



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 16781/276 BEDL

In re patent application of

Daniel CAPUT et al.

Serial No. 07/659,408

Group Art Unit:

Filed: April 25, 1991

Examiner:

For: URATE OXIDASE ACTIVITY PROTEIN,
RECOMBINANT GENE CODING THEREFOR,
EXPRESSION VECTOR, MICRO-ORGANISMS AND
TRANSFORMED CELLS

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 C.F.R. §§ 1.821-1.825

The Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Sir:

The undersigned hereby states that the content of
the attached papers and the computer readable copy of the
Sequence Listing, submitted in accordance with 37 C.F.R.
§1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Date: October 15, 1991

Paul C. Kimball
Registration No. 34,641

FOLEY & LARDNER
P. O. Box 299
Alexandria, Virginia 22313
(703) 836-9300



Fold and Gardner, Schwartz, Jeffery,
Schiff, Mark, Blumenthal and Evans
P.O. Box 199
Alexandria, VA 22313-0299

Daniel Caput
07/659,408
April 25, 1991

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Mailed: 5-15-91

#3

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with one or more of the requirements of 37 CFR §§ 1.821 through 1.825 as follows:

- ☐ 1. This application clearly fails to comply with the collective requirements of §§ 1.821 through 1.825. Applicant's attention is directed to these regulations, a copy of which is attached.
- ☐ 2. This application does not conform exclusively to the requirements of §§ 1.821 through 1.825. The non-conforming material should be deleted. § 1.821(b).
- ☐ 3. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." § 1.821(c).
- ☐ 4. This application does contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." However, the "Sequence Listing" does not comply with the requirements of §§ 1.821 through 1.825 as follows:
 - ☐ a. The sequence data does not comply with the symbol and format requirements of paragraphs (b) through (p) of § 1.822. Specifically: _____
 - ☐ b. The "Sequence Listing" does not comply with the location and page requirements of paragraph (a) of § 1.823.
 - ☐ c. The "Sequence Listing" does not comply with the information requirements of paragraph (b) of § 1.823. Specifically: _____
 - ☐ d. Other: _____
- ☐ 5. The description and/or claims of the patent application mention a sequence that is set forth in the "Sequence Listing" but reference is not properly made to the sequence by use of a sequence identifier as required by § 1.821(d).
- ☒ 6. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by § 1.821(e).
- ☐ 7. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the computer readable form does not comply with the requirements of § 1.824. Specifically: _____
- ☐ 8. A statement that the content of the paper and computer readable copies are the same has not been submitted as required by § 1.821(f).
- ☐ 9. The amendment to or replacement of the paper and/or computer readable copies of the "Sequence Listing" does not comply with the requirements of § 1.825(a) through (c).
- ☐ 10. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable. Applicant must provide a substitute copy of the data in computer readable form accompanied by a statement that the substitute data is identical to that originally filed. § 1.825(d). Specifically: _____
- ☐ 11. Other: _____

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE ABOVE REQUIREMENTS. Failure to comply with the above requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. Direct the response to, and any questions about, this notice to the undersigned. A copy of this notice MUST be returned with your response.

Dora Stroud



Examiner Group